The association between gut microbiota, cholesterol gallstones, and colorectal cancer

Sama Rezasoltani¹, Amir Sadeghi², Ebrahim Radinnia³, Ali Naseh⁴, Zahra Gholamrezaei¹, Mehdi Azizmohammad Looha¹, Abbas Yadegar³

¹Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
²Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
³Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT
Gut microbiota play critical roles in maintaining the human health in several aspects. Bile acids (BAs) are endogenous cholesterol-derived molecules that can be modified by the gut microbiota and act as signaling molecules in the regulation of host metabolic and physiology processes. Gut microbiota release many enzymes that are capable to perform considerable modifications on BAs such as bile salt hydrolases (BSH), 7α-dehydroxylase (CYP7A), and hydroxysteroid dehydrogenase (HSDH). These enzymatic roles can change in the gut microbiota composition, cause alteration in BAs profile and metabolism and even gallstone formation. Patients with 15 years of asymptomatic gallstone have increased risk for colorectal cancer (CRC), which may be related to altered gut microbiota, changes in bile metabolism, as well as cellular and molecular effects in the proximal colon. In gallstone-associated CRC patients, the association between consensus molecular subtypes of CRC should be clarified to identify if specific pathways are related.

Keywords: Gut microbiota, Cholesterol gallstones, Colorectal cancer.

(Please cite as: Rezasoltani S, Sadeghi A, Radinnia E, Naseh A, Gholamrezaei Z, Looha A, et al. The association between gut microbiota, cholesterol gallstones and colorectal cancer. Gastroenterol Hepatol Bed Bench 2019;12(Suppl.1):S8-S13).

Introduction

Gut microbiota
There are $10^{14}$-$10^{15}$ bacteria residing in the human gastrointestinal tract, and estimated to outnumber the host own cells by 10 to $1$ (1). The total number of bacteria in a 70 kg "reference man" has been calculated to be $3.8 \cdot 10^{13}$ (2). The gut microbiota consists of more than 1000 different bacterial species (3), and while they vary extensively across populations, a core microbiota consisting of a fraction of these bacterial species can be recognized in large cohorts of healthy individuals (3, 4). There is a mutual relationship between the commensal intestinal microbiota and the host. Gut microbiota help in metabolism of nutrients and micronutrients the host body cannot metabolize (5). Notably, gut microbiota help control the host physiology beyond the intestinal lumen. It can signal to host body cells and control their activity (6, 7). Indeed, microbial metabolites and products such as bile acids (BAs), short chain fatty acids, amino acids, and steroid hormones are transported from the intestinal lumen environment into bloodstream and delivered to the host cells (8). These microbial metabolites are signaling molecules, and various organs of the host express certain receptors for them (9). Such receptors control cellular pathways and are exactly under the influence of microbial signaling molecules. Hence, gut microbiota plays an important role in the host physiology, even health and disease, through regulation of microbial signaling molecules for cellular receptors (Table 1).
Further, gut microbiota is easily changeable through environmental factors such as food diets, social contact, as well as regular probiotic and antibiotic consumption (11). Regarding the critical role of gut microbiota as a regulator of host physiology, it might be a novel and powerful candidate for treating human diseases (12).

**Impact of gut microbiota on host physiology**

Gut microbiota interact symbiotically with the host, influence several aspects of the host's physiology (20) and produce nutrients and micronutrients in the human body. For instance, they assist in differentiation of intestinal epithelial cells (IECs), development of immune system (21), improvement of the bioavailability of nutrients in the food, elimination of the invading pathogenic bacteria (22), the gut barrier function (23), control of the host behavior (24, 25), and bone homeostasis (26). On the other hand, gut microbiota can contribute as a key regulator to host metabolic dysfunction beyond IECs (27). Further, there is a strong relationship between microbial agents and hormone production and release. Indeed, enteroendocrine cells produce and secrete a number of hormones including cholecystokinin (CCK), peptide tyrosine-tyrosine (PYY), glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and serotonin (5-HT), which have regulatory roles in metabolic processes including insulin sensitivity, glucose tolerance, and fat storage. Release of these hormones can be regulated by the presence of gut microbiota and their metabolites (28).

**Bile acids**

BAs are synthesized from cholesterol in the liver and stored in the gallbladder to be secreted in the duodenal lumen upon food intake in order to facilitate fat digestion (29). BAs act on nuclear receptors, such as farnesoid X receptor, which are involved in the metabolism of triglyceride, sterol, and carbohydrate. BAs are critical signaling molecules in the host, as they interact either locally or systemically with specific cellular receptors, especially TGR5 and farnesoid X receptor (5). These functions of signaling influence systemic lipid, cholesterol, and energy metabolism, as well as intestinal electrolyte balance and immune homeostasis (30). Synthesis of BAs is under negative feedback control through activation of the nuclear receptor farnesoid X receptor in the ileum and liver. BAs act as detergents with a critical role in solubilizing fat soluble vitamins and dietary lipids to help their absorption in the small intestine (31). Also, BAs inhibit bacterial

| Table 1. Gut microbiota alterations associated with different types of diseases |
|-------------------------------------------------|-------------------------------------------------|
| **Bacterial agents/Diseases**                      | **Alteration in gut microbiota composition**                          |
| Obesity                                          | Certain gut bacteria alterations are associated with severe obesity |
| Firmicutes/Bacteroidetes ratio ↓                 | Methanobrevibacter smithii significantly increase in lean individuals |
| Bacteroidetes ↓                                  | Changes in *Bacteroides* spp. quantity in Crohn’s disease patients are |
| *Lactobacillus* ↑                               | observed compared to healthy individuals |
| *Methanobrevibacter smithii* ↓                   | Higher bacterial diversity in Celiac disease patients versus control group are observed |
| *Bacteroides ovatus* ↑                           |                |
| *Bacteroides vulgatus* ↑                         |                |
| *Bacteroides uniformis* ↓                        |                |
| Anorexia                                         |                |
| *Methanobrevibacter smithii* ↑                   |                |
| Crohn’s Disease                                  |                |
| *Bacteroides ovatus* ↑                           |                |
| *Bacteroides vulgatus* ↑                         |                |
| *Escherichia coli* ↓                             |                |
| *Clostridium cocoides* ↓                         |                |
| Celiac disease                                  |                |
| *Type 2 Diabetes*                                |                |
| Bacteroidetes/Firmicutes ratio ↑                 |                |
| *Bacteroides-Prevotella* ↑                       |                |
| *Clostridium cocoides-Eubacterium rectale* ↓     | shifts in gut microbiota are associated with disease |
| *Firmicutes* ↓                                   |                |
| *Clostridia* ↓                                   |                |
The association between gut microbiota, cholesterol gallstones and colorectal cancer

Growth or bacterial infections in the small intestine (32). In the lumen environment, microbial bile salt hydrolases (BSHs) deconjugate BAs and cause bile resistance to the gut microbiota (33). Deconjugated BAs can be absorbed more easily across the IECs and are more hydrophobic than conjugated ones (34). Then, they can be modified to secondary BAs by enzymatic activities of the intestinal bacteria. These enzymatic activities result in the modification of the primary BAs [cholic acid (CA) and chenodeoxycholic acid (CDCA)] to the secondary BAs [deoxycholic acid (DCA) and lithocholic acid (LCA)]. Overall, given the important role of microbial metabolites and function in BAs regulation and modification, commensal bacteria may be a key regulator for enterohepatic recycling of BAs, and creating resistance to Clostridium difficile infections (35).

Intestinal crosstalk between BAs and microbiota

Today, there is an increasing interest in the microbiota with respect to diseases of the gastroenterological tract including the liver and biliary system (36, 37). Potential mechanisms in the gut–liver axis terminate to gallbladder disease and carcinogenesis in different types of organ (38, 39). Gut microbiota contains many enzymes that are capable to perform modifications of BAs (40, 41). As mentioned above, the most important microbial modification of BAs in the gut is deconjugation by BSH, which is the first step of microbial modification of BAs (40) plentifully expressed by all bacterial phyla in the gut (41). Once entered into the duodenum, BAs come into contact with bacterial species with BSH activity such as

Figure 1. The enterohepatic circulation, BAs physiology and microbial BAs modification in the gut.
Streptococcus and Lactobacillus. It is unknown why gut microbiota express BSH; it may be because deconjugation reduces BAs antimicrobial properties and toxicity to the microbiota and makes it available for subsequent modifications by the gut microbiota. On the other hand, microbial 7α-dehydroxylase enzyme is required for the production of secondary BAs deoxycholic (DCA) and lithocholic (LCA) acids. Unlike BSH, 7α-dehydroxylase enzyme has only been found in a few Clostridium species including Clostridium cluster XI and XVI which are low abundant taxa in the gut (42). Above all, hydroxysteroid dehydrogenase (HSDH) enzyme induces BAs biotransformation and is abundantly produced by gut microbiota. It catalyzes the oxidation of BAs to form oxo-BAs intermediates (42, 43). The main function of HSDH is still unrecognized, but it is speculated to generate bacterial energy through producing and reducing equivalents for cellular biosynthetic reactions (Figure 1) (40, 44). Based on these gut microbial enzymatic roles, it is thought that altered gut microbiota may be a cause and an effect of altered BAs profile and even gallstone formation. These gut microbiota alterations may further affect the intestinal epithelium cells, with progressive cellular and molecular changes in carcinogenesis (45).

On the other hand, BAs can modulate gut microbial composition directly and indirectly through activation of innate immune genes in the small intestine. Thus, altered BAs profile may result in altered signaling via BAs receptors and affect host metabolism while also causing altered gut microbiota composition (40, 41).

Gallstone disease and cancer risk
In the adult population of Western countries, 10-15% develop gallstones. Cholecystectomy is a common treatment for symptomatic gallstones and other gallbladder conditions (46). As mentioned earlier, according to gut microbial enzymatic roles, it is thought that altered gut microbiota composition may be a cause and an effect of altered BAs profile and even gallstone formation (45). Patients with asymptomatic gallstones at baseline had an increased risk for cancer at all gastrointestinal sites in particular for right-sided colorectal cancers (CRC). The risk of CRC increased significantly after 15 years with asymptomatic gallstone. It has been known that, cancer in certain organ sites could be explained by altered metabolic or endocrine pathways; thus, the clearest mechanism between gallstone disease and CRC may be related to altered gut microbiota, changes in bile metabolism, as well as cellular and molecular effects in the proximal colon (45, 47). Hence, gallstones contribute to increased risk for invasive CRC. Indeed, detection of certain CRC-associated bacteria raises the detection accuracy of screened CRC cases (48-50), which may be of particular importance for those with detected with silent gallstones (45). Asymptomatic gallstones may demonstrate a future CRC risk and underlying mechanism which needs to be further identified. Mechanistic links between gallstone pathology and neoplasia demand to be better understood. In particular, it should be examined how changes in bile metabolism may have local and systemic effects on human cells through molecular pathways. Overall, healthy gut microbiota can help our bodies to maintain a healthy digestion system.

Conclusion
Gut microbiota contains several enzymes that are capable to provide critical modifications of BAs. Based on these critical enzymatic roles, it is thought that altered gut microbiota may be a cause and an effect of altered BAs profile and even gallstone formation. Further, the association between gallstone disease and CRC may be related to altered gut microbiota, changes in bile metabolism, as well as cellular and molecular effects in the gut. Indeed, with good flora, gut inflammation will probably occur less frequently and digestive processes will run more smoothly. All of these lead to less gallstone formation. Also, changes in BAs excretion and profile are important for the human health and disease. In patients with gallstone-related CRC, any links with the consensus molecular subtypes should be explored to identify if specific pathways are associated.

Conflict of interests
The authors declare that they have no conflict of interest.

References
1. Ganji L, Alebouyeh M, Shirazi MH, Eshraghi SS, Mirshafiey A, Ebrahimi Daryani N, et al. Dysbiosis of fecal microbiota and high frequency of Citrobacter, Klebsiella spp.,
and Actinomycetes in patients with irritable bowel syndrome and gastroenteritis, Gastroenterol Hepatol Bed Bench 2016; 9: 325-330.

2. Jahani-Sherafat S, Alebouyeh M, Moghim Sh, Ahmadi Amoli H, Ghasemian-Saefei H. Role of gut microbiota in the pathogenesis of colorectal cancer; a review article, Gastroenterol Hepatol Bed Bench 2018;11:101-109.

3. Rezasoltani S, Asadzadeh-Aghdaei H, Nazemalhosseini-Mojarrad E, Dabiri H, Ghanbari R, Zali MR. Gut microbiota, epigenetic modification and colorectal cancer. Iran J Microbiol 2017; 9: 55-63.

4. Rostami Nejad M, Ishaq S, Al Dulaimi D, Zali MR, Rostami K. The role of infectious mediators and gut microbiome in the pathogenesis of celiac disease. Arch Iran Med 2015; 18:244-9.

5. Rezasoltani S, Dabiri H, Asadzadeh-Aghdaei H, Akhvan Sepahi A, Modarressi MH. Nazemalhosseini-Mojarrad E. The gut microflora assay in patients with colorectal cancer: in feces or tissue samples? Iran J Microbiol 2019;11:1-6.

6. Wu H, Tremaroli V, Backhed F. Linking Microbiota to Human Diseases: A Systems Biology Perspective. TEM 2015; 26:758-70.

7. Joyce SA, Gahan CG. The gut microbiota and the metabolic health of the host. Curr Opin Gastroenterol 2014; 30:120-7.

8. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr 2018;57:1-24.

9. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012;489:242-9.

10. Clemente JC, Ursell LK, Parfrey LW, Knight R. The Impact of the Gut Microbiota on Human Health: An Integrative View. Cell 2012;148:1258.

11. Fouhy F, Ross RP, Fitzgerald GF, Stanton C, Cotter PD. Composition of the early intestinal microbiota, Gut Microbes 2012;3:203-20.

12. Rezasoltani S, Nazemalhosseini Mojarrad E, Norouzinia M, Asadzadeh Aghdaei H. The necessity of gut microbiome characterization in diseases prevention and therapy, Gastroenterol Hepatol Bed Bench 2017;10:150-1.

13. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc. Natl. Acad.Sci 2005;102:11070-5.

14. Pflughoeft KJ, Versalovic J. Human microbiome in health and disease. Annu. Rev Pathol 2012;7:99-122.

15. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009;1:6-14.

16. Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One 2009;4:e7125.

17. Dicksved J, Halfvarson J, Rosenquist M, Järnerot G, Tysk C, Apajalaiti J, et al. Molecular analysis of the gut microbiota of identical twins with Crohn’s disease. ISME J 2008;2:716-27.

18. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2001;145:745-57.

19. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000;22:283-97.

20. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science 2012;336:1262-7.

21. Arrieta MC, Finlay BB. The commensal microbiota drives immune homeostasis. Front Immunol 2012;3:33.

22. Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol 2007; 19:59-69.

23. Sanos SL, Bui VL, Mortha A, Oberle K, Heners C, Johner C, Diefenbach A. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin-22-producing NKP46+ cells. Nat Immunol 2009;10:83-91.

24. Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neuro Gastroenterol Motil 2011;23:255-64.

25. Díaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci 2011;108:3047-52.

26. Sjögren K, Engdahl C, Henning P, Lerner UH, Tremaroli V, Lagerquist MK, et al. The gut microbiota regulates bone mass in mice. J Bone Miner Res 2012;27:1357-67.

27. Larsson E, Tremaroli V, Lee YS, Kor en O, Nookaew I, Fricker A, et al. Analysis of gut microbiol regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut 2012;61:1124-31.

28. Martin AM, Sun1 EW, Geraint B. Rogers GB, Keating DJ. The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release. Front Physiol 2019;10:428.

29. Reshefnyak VI. Physiological and molecular biochemical mechanisms of bile formation. World J Gastroenterol 2013; 19:7341-60.

30. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904.

31. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647-58.

32. Lorenzo-Zúñiga V, Bartoli R, Planas R, Hofmann AF, Viñado B, Hagey LR, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003;37:551-7.
33. Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci 2008;105:13580-5.

34. Stremmel W, Hofmann AF. Intestinal absorption of unconjugated dihydroxy bile acids: non-mediation by the carrier system involved in long chain fatty acid absorption. Lipids 1999;25:11-6.

35. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015;517:205-8.

36. Saltykova IV, Petrov VA, Logacheva MD, Ivanova PG, Merzlikin NV, Sazonov AE, et al. Biliary Microbiota, Gallstone Disease and Infection with Opisthorchis felineus. PLoS Negl Trop Dis 2016;10:e0004809.

37. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014;12:661-72.

38. Tabibian JH, Varghese C, LaRusso NF, O'Hara SP. The Enteric Microbiome in Hepatobiliary Health and Disease. Liver Int 2016;36:480-7.

39. Verdier J, Luedde T, Sellge G. Biliary Mucosal Barrier and Microbiome. Viszeralmedizin 2015;31:156-61.

40. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241-59.

41. Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci 2008;105:13580-1.

42. Wells JE, Berr F, Thomas LA, Dowling RH, Hylemon PB. Isolation and characterization of cholic acid 7alpha-dehydroxylating fecal bacteria from cholesterol gallstone patients. J Hepatol 2000;32:4-10.

43. Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM. Role of the microbiome in energy regulation and metabolism. Gastroenterology 2014;146:1525-33.

44. Skalhegg BA. On the 3 alpha-hydroxysteroid dehydrogenase from Pseudomonas testosteroni. Purification and properties. Eur J Biochem 1974;46:117-25.

45. Soreide K. Gallstone Disease and Cancer Risk: Finding the Bug in the System. Gastroentrology 2017;152:1825-8.

46. Shaffer EA. Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 2017;13:2202-9.

47. Chong C, Cox MR, Eslick GD. Gallstones are associated with colonic adenoma: a meta-analysis. World J Surg 2012;36:2202-9.

48. Liang Q, Chiu J, Chen Y, Huang Y, Higashimori A, Fang J, et al. Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer. Clin Cancer Res 2017;23:2061-70.

49. Rezasoltani S, Sharafkhah M, Asadzadeh-Aghdai H, Nazemalhosseini-Mojarrad E, Dabiri H, Akhavan Sepahi A, et al. Applying simple linear combination, multiple logistic and factor analysis methods for candidate fecal bacteria as novel biomarkers for early detection of adenomatous polyps and colon cancer. J Microbiol Methods 2018;155:82-8.

50. Rezasoltani S, Asadzadeh-Aghdai H, Dabiri H, Akhavan Sepahi A, Modarressi MH, Nazemalhosseini-Mojarrad E. The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. Microb Pathog 2018;124:244-9.